Company Profile
We're working hard to bring you this company's profile. Register here to get an alert as soon we're done.
In the meantime, if you are interested in participating in placements on this stock click "Follow" on the toolbar above.
We're working on profiling this company soon. Let us know you're interested by sending us a request here »
We're working hard to bring you this company's profile. Register here to get an alert as soon we're done.
In the meantime, if you are interested in participating in placements on this stock click "Follow" on the toolbar above.
The ASX200 closed the day up more than a per cent (1.08%). All sectors bar one finished in the gr...
Read ArticleThe ASX200 is up nearly a per cent – in a harmonious flow with futures predictions. Every sector...
Read ArticlePYC Therapeutics (ASX:PYC) has completed Dose Range Finding (DRF) studies for its investigational dr...
Read ArticleIt’s been three consecutive months that US inflation data has come in higher than expected and, with...
Read ArticlePYC Therapeutics (ASX:PYC) has announced the successful closure of the institutional compone...
Read ArticleHere’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 2...
Read ArticlePYC Therapeutics (ASX:PYC) has announced the results of a study conducted in three-dimension...
Read ArticlePYC has developed a new drug candidate for the >5 million people worldwide[1] with Polycystic Ki...
Read Article4DX surges more than 50pc after an update from the US PYC Therapeutic said its fourth drug candidat...
Read ArticlePYC Therapeutics (ASX:PYC) has held a pre-IND meeting with the US FDA and announced it has a...
Read ArticlePYC to take ADOA drug to human clinical trials Imugene provides update of its Phase 1 MAST (Metasta...
Read ArticlePYC Therapeutics (ASX:PYC) has announced that the Safety Review Committee (SRC) governing on...
Read ArticlePYC Therapeutics (ASX:PYC) has completed dosing for patients in cohort one of the Platypus c...
Read ArticleASX to open higher despite a drop on Wall Street Tonight’s US CPI data weighs on markets These two...
Read ArticlePYC receives Fast Track designation from the US FDA BCAL Diagnostics announces breakthrough results...
Read ArticlePYC Therapeutics to advance to Phase 2 clinical trial Osteopore announced new CEO and non-executive...
Read ArticlePYC Therapeutics (PYC) doses the first patient with drug candidate VP-001, designed to treat blindin...
Read ArticleASX falls 0.17% ahead of Chalmers dropping The Budget on the nation Financials led the pack today,...
Read ArticleCardieX jumps 16pc after getting FDA clearance for CONNEQT Pulse CONNEQT Pulse is a world first mul...
Read ArticlePYC Pharmaceuticals (PYC) lands approval from the US FDA to begin human trials of a new drug to trea...
Read ArticleRhythm plunged 45% this morning after announcing some TGA news The FDA has cleared PYC Therapeutics...
Read ArticleSonic has taken a stake in Microba Immutep enters into second deal with Merck (Germany) and Pfizer ...
Read ArticlePYC Therapeutics (PYC) completes single-dose toxicology of its investigational Retinitis Pigmentosa...
Read ArticleHighlights: The ASX 200 benchmark index closed up today, gaining 0.41% to end at 6,496.20 points...
Read ArticlePYC Therapeutics (PYC) adds a third drug program for the treatment of Phelan McDermid Syndrome (PMS)...
Read ArticlePYC Therapeutics and Race Oncology announce new RNA programs Recce Pharma accelerates its clinical...
Read ArticleThe ASX 200 will open higher on Tuesday despite another selloff on Wall Street Investors dump risky...
Read ArticleHighlights PYC Therapeutics has completed its pharmacokinetic (PK) studies in Non-Human Primates...
Read ArticleBiotech company PYC Therapeutics (PYC) has increased its stake in Vision Pharma to 93.5 per cent T...
Read ArticleIt’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and...
Read ArticleIt’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 los...
Read ArticlePYC Therapeutics (ASX:PYC) says it has completed a key translational milestone for its RNA p...
Read ArticleThe hot debut of Evolution Energy Minerals (ASX:EV1) was not enough to save the ASX resources sector...
Read ArticleThe ASX 200 Health Index (XHJ) is down by 0.30% at the time of writing, compared to the broader inde...
Read ArticleThe ASX posted steady gains to start the week on Monday, with investors preferences leaning towards...
Read ArticlePharmAust has had a busy and productive quarter, setting the foundations for the commercialisation o...
Read ArticleSummary The S&P/ASX200ended 60 points or 0.31% higher at 7,354. The index gained as much as...
Read ArticleSummary The S&P/ASX200 traded higher by 20 points or 0.27% at 7,352 by the afternoon. The i...
Read ArticleThe ASX finished in positive territory, although short of an all-time high. The ASX 200 closed 0.15...
Read ArticlePYC Therapeutics (ASX:PYC), a company developing RNA therapeutics for inherited diseases, ha...
Read ArticleThe ASX 200 close 0.19 per cent lower than Friday at 7,282 points and the ASX Emerging Companies Ind...
Read ArticleThe PYC Therapeutics Ltd (ASX: PYC) share price has risen 170% in a year and 13% this month, follow...
Read ArticlePYC Therapeutics (ASX:PYC), a biotechnology company developing precision RNA therapeutics, h...
Read ArticleThe ASX finished in the red today dragged down by resources and energy. Materials and Energy stocks...
Read ArticleSource: GoYong,Shutterstock Summary PYC Therapeutics’ investigational drug, VP-001, has restore...
Read ArticlePYC Therapeutics (ASX:PYC), a biotechnology company developing a new generation of precision...
Read ArticleThe PYC Therapeutics Ltd (ASX: PYC) share price leapt 9% higher to 18 cents today before slipping t...
Read ArticleS&P Dow Jones Indices has announced the quarterly rebalance of the entire S&P/ASX index hier...
Read ArticleZelira Therapeutics (ASX:ZLD) chief Dr Richard Hopkins confirms what your columnist suspected was a...
Read ArticleHere it is – your weekly look at the stocks fund managers are buying (and selling). Trading Places i...
Read ArticleDrug development company, PYC Therapeutics (PYC) has added six new precision medicines to its retin...
Read ArticlePYC Therapeutics (PYC) recently finalised its lead drug molecule in the final quarter of 2019 Its l...
Read ArticleThere are many reasons why a company might change its name, from being taken over to hiding a shady...
Read ArticleDid the doc say to take one pill twice daily, or two tablets once daily? When it comes to correct me...
Read ArticleDid you know that a hard-working stallion ejaculates 100 times more sperm than the average bloke? Gi...
Read ArticleOne director has this week put more skin in the game to take his family’s total stake to over $20m —...
Read ArticleEver since the advent of TV, worried parents have cautioned their kids that too much time in front o...
Read ArticleBiotechnology company Phylogica (ASX: PYC) is one step closer to finding a treatment for the leading...
Read ArticleOn Stockhead today: Aussie small caps trying to tackle the opioid crisis, which car manufacturers wi...
Read ArticleA drug delivery platform developed by biotechnology company Phylogica (ASX: PYC) has been shown to b...
Read ArticleStockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade....
Read ArticleAustralia is known to have one of the world’s best health system, which provides quality, safe and r...
Read ArticlePerth-based biotech company Phylogica (ASX: PYC) has reported positive early stage results from a pi...
Read ArticleStockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade....
Read ArticleBiotechnology company Phylogica (ASX: PYC) has unveiled favourable lab results in relation to its ti...
Read ArticleMedical tech company Phylogica (ASX: PYC) has cleared an important hurdle in the development of its...
Read ArticleOpen an account with an online broker of your choice. If you do not have an existing broker, consider Mawson Graham's A$9.50 flat fee platform.
Sign up now »Place your order however you wish. If you need advice on buying or selling, you should seek the assistance of a full service financial adviser experienced in small cap equities.